Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 2/20 | 0.44 |
| ▸ | ALPG | P10696 | 2/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26488900 | 0.89 | ALDH1A1 (0.61) | SMN1; SMN2ESR1KMT2AALDH1A1POLB | |
| SCHEMBL4298077 | 0.85 | KMT2A (0.57) | SMN1; SMN2ESR1KMT2AALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL3122278 | 0.85 | ALDH1A1 (0.56) | SMN1; SMN2ESR1KMT2AALDH1A1POLB | |
| SCHEMBL1178451 | 0.84 | KMT2A (0.56) | SMN1; SMN2ESR1KMT2AALDH1A1POLB | |
| SCHEMBL23723498 | 0.83 | KMT2A (0.52) | SMN1; SMN2ESR1KMT2AALDH1A1POLB | |
| Oxalic Acid SCHEMBL10364075 | 0.82 | ALDH1A1 (0.51) | SMN1; SMN2ESR1KMT2AALDH1A1POLB | |
| SCHEMBL16019687 | 0.81 | ALDH1A1 (0.51) | SMN1; SMN2ESR1KMT2AALDH1A1POLB | |
| SCHEMBL369240 | 0.81 | ALPL (0.54) | SMN1; SMN2ESR1KMT2AALDH1A1POLB | |
| SCHEMBL2962697 | 0.81 | KMT2A (0.57) | SMN1; SMN2ESR1KMT2AALDH1A1POLB | |
| SCHEMBL6947633 | 0.80 | ESR1 (0.52) | ESR1KMT2AALDH1A1POLBALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456781-B1 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ACYLOXYALKYLENE PHENYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES | BAYER IP GMBH (DE) | 2017-06-21 | — | — | EP | claimed |
| US-9096639-B2 | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylene phenyl derivatives, methods for the production thereof and use thereof for treating diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | claimed |
| US-20120232042-A1 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ACYLOXYALKYLENE PHENYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-13 | — | — | US | claimed |
| EP-2456781-A2 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ACYLOXYALKYLENE PHENYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES | Bayer Pharma Aktiengesellschaft (DE) | 2012-05-30 | — | — | EP | claimed |
| WO-2011009530-A2 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ACYLOXYALKYLENE PHENYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | WO | claimed |
| EP-0669357-B1 | N-alkyl-n'-aryl-p-phenylenediamines as modifiers for epoxy resins | CIBA SC HOLDING AG (CH) | 1999-11-24 | — | — | EP | claimed |
| US-5503936-A | CURING A MIXTURE OF GLYCIDYL ETHER OR AROMATIC AMINE, A HARDENER OR CURING AGENT AND N-1,3-DIMETHYLBUTYL-N'-DIMETH-YL-BUTYL-N'- OR N,N'-BIS(1,4-DIMETHYLPENTYL-P-PHENYLENEDIAMINE; COMPOSITES; STRENGTH | CIBA-GEIGY CORPORATION (US) | 1996-04-02 | — | — | US | claimed |
| EP-0669357-A2 | N-alkyl-n'-aryl-p-phenylenediamines as modifiers for epoxy resins | CIBA-GEIGY AG (CH) | 1995-08-30 | — | — | EP | claimed |
| US-9757944-B2 | Liquid jet head and method for producing same, and liquid jet apparatus and image forming apparatus | RICOH COMPANY, LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| EP-2456781-B1 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ACYLOXYALKYLENE PHENYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES | BAYER IP GMBH (DE) | 2017-06-21 | — | — | EP | disclosed |
| US-20170043580-A1 | LIQUID JET HEAD AND METHOD FOR PRODUCING SAME, AND LIQUID JET APPARATUS AND IMAGE FORMING APPARATUS | RICOH COMPANY, LTD. (JP) | 2017-02-16 | — | — | US | disclosed |
| US-9096639-B2 | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylene phenyl derivatives, methods for the production thereof and use thereof for treating diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-8921555-B2 | Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones | MERCK SHARP & DOHME CORP. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2366704-B1 | Inhibitors of serine proteases | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20090318396-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009152171-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | GILEAD SCIENCES, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-0669357-B1 | N-alkyl-n'-aryl-p-phenylenediamines as modifiers for epoxy resins | CIBA SC HOLDING AG (CH) | 1999-11-24 | — | — | EP | disclosed |
| US-5503936-A | CURING A MIXTURE OF GLYCIDYL ETHER OR AROMATIC AMINE, A HARDENER OR CURING AGENT AND N-1,3-DIMETHYLBUTYL-N'-DIMETH-YL-BUTYL-N'- OR N,N'-BIS(1,4-DIMETHYLPENTYL-P-PHENYLENEDIAMINE; COMPOSITES; STRENGTH | CIBA-GEIGY CORPORATION (US) | 1996-04-02 | — | — | US | disclosed |
| EP-0669357-A2 | N-alkyl-n'-aryl-p-phenylenediamines as modifiers for epoxy resins | CIBA-GEIGY AG (CH) | 1995-08-30 | — | — | EP | disclosed |
| EP-0258033-A2 | Dihydropyridine anti-allergic and anti-inflammatory agents | Pfizer Limited (GB) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232042-A1 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ACYLOXYALKYLENE PHENYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES | CYP19A1, HSD17B11, SHBG | SMN1; SMN2 2299/4885ESR1 11/4885KMT2A 320/4885 |
| US-20090318396-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | ADRB1, ADRB2, ADRB3 | SMN1; SMN2 2544/4885ESR1 480/4885KMT2A 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.